» Articles » PMID: 2596246

High Plasma Levels of Extrinsic Pathway Inhibitor and Low Levels of Other Coagulation Inhibitors in Advanced Cancer

Overview
Journal Acta Chir Scand
Specialty General Surgery
Date 1989 Aug 1
PMID 2596246
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Serial determinations of plasma coagulation inhibitor levels were performed with chromogenic substrate activity assays in 7 patients with cancer. At time of diagnosis normal median activities of Antithrombin, Protein C, Heparin Cofactor II and Extrinsic Pathway Inhibitor were found. The inhibitor activities changed significantly with the progress of malignant disease; Antithrombin, Protein C and Heparin Cofactor II decreased whereas Extrinsic Pathway Inhibitor increased. Determinations in 13 additional patients in the terminal phase of cancer confirmed this finding. The inhibitor activities were expressed in per cent of a pooled reference plasma. In the total series of 20 patients studied, median activity of Extrinsic Pathway Inhibitor was 183% (range 61-378%) and significantly (p less than 0.005) above age-adjusted normal reference 10 days (range 1-20 days) prior to death. Median activities of Antithrombin was 59% (range 20-109%), of Protein C 54% (range 24-130%) and Heparin Cofactor II 59% (range 33-110%), all significantly below age adjusted normal reference (p less than 0.001). The coagulation inhibitor levels seem related to the stage of disease in patients with cancer.

Citing Articles

Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer.

Englisch C, Moik F, Thaler J, Koder S, Mackman N, Preusser M Haematologica. 2023; 109(4):1128-1136.

PMID: 37822244 PMC: 10985431. DOI: 10.3324/haematol.2023.283581.


Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy.

Wojtukiewicz M, Mysliwiec M, Matuszewska E, Sulkowski S, Zimnoch L, Politynska B Biomolecules. 2021; 11(5).

PMID: 33947134 PMC: 8146081. DOI: 10.3390/biom11050663.


Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.

Tinholt M, Vollan H, Sahlberg K, Jernstrom S, Kaveh F, Lingjaerde O Breast Cancer Res. 2015; 17:44.

PMID: 25882602 PMC: 4423106. DOI: 10.1186/s13058-015-0548-5.


Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study.

Tinholt M, Viken M, Dahm A, Vollan H, Sahlberg K, Garred O BMC Cancer. 2014; 14:845.

PMID: 25407022 PMC: 4251949. DOI: 10.1186/1471-2407-14-845.


Overexpression of tissue factor pathway inhibitor in CHO-K1 cells results in increased activation of NF-κB and apoptosis mediated by a caspase-3 independent pathway.

Skretting G, Iversen N, Myklebust C, Dahm A, Sandset P Mol Biol Rep. 2012; 39(12):10089-96.

PMID: 22932941 DOI: 10.1007/s11033-012-1882-7.